 DUBLIN, June 24, 2021 PRNewswire -- Theravance Biopharma, Inc. NASDAQ: TBPH Theravance Biopharma, a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, announced today that it intends to offer its ordinary shares in an underwritten public offering. Theravance Biopharma also intends to grant the underwriters a 30-day option to purchase up to an additional 15 of the number of ordinary shares in the offering. 